272 related articles for article (PubMed ID: 19834474)
1. In central obesity, weight loss restores platelet sensitivity to nitric oxide and prostacyclin.
Russo I; Traversa M; Bonomo K; De Salve A; Mattiello L; Del Mese P; Doronzo G; Cavalot F; Trovati M; Anfossi G
Obesity (Silver Spring); 2010 Apr; 18(4):788-97. PubMed ID: 19834474
[TBL] [Abstract][Full Text] [Related]
2. Impaired synthesis and action of antiaggregating cyclic nucleotides in platelets from obese subjects: possible role in platelet hyperactivation in obesity.
Anfossi G; Russo I; Massucco P; Mattiello L; Doronzo G; De Salve A; Trovati M
Eur J Clin Invest; 2004 Jul; 34(7):482-9. PubMed ID: 15255785
[TBL] [Abstract][Full Text] [Related]
3. Interaction of antiplatelet drugs in vitro: aspirin, iloprost, and the nitric oxide donors SIN-1 and sodium nitroprusside.
Negrescu EV; Grünberg B; Kratzer MA; Lorenz R; Siess W
Cardiovasc Drugs Ther; 1995 Aug; 9(4):619-29. PubMed ID: 8547213
[TBL] [Abstract][Full Text] [Related]
4. Organic nitrates and compounds that increase intraplatelet cyclic guanosine monophosphate (cGMP) levels enhance the antiaggregating effects of the stable prostacyclin analogue iloprost.
Anfossi G; Massucco P; Mularoni E; Cavalot F; Mattiello L; Trovati M
Prostaglandins Leukot Essent Fatty Acids; 1993 Nov; 49(5):839-45. PubMed ID: 7508131
[TBL] [Abstract][Full Text] [Related]
5. Studies on inhibition of human platelet function by sodium nitroprusside. Kinetic evaluation of the effect on aggregation and cyclic nucleotide content.
Anfossi G; Russo I; Massucco P; Mattiello L; Balbo A; Cavalot F; Trovati M
Thromb Res; 2001 May; 102(4):319-30. PubMed ID: 11369425
[TBL] [Abstract][Full Text] [Related]
6. Nitric oxide and prostacyclin modulate the alterations in cardiac action potential duration mediated by platelets during ischaemia.
Goulielmos NV; Enayat ZE; Sheridan DJ; Cohen H; Flores NA
Cardiovasc Res; 1995 Nov; 30(5):788-98. PubMed ID: 8595628
[TBL] [Abstract][Full Text] [Related]
7. Loss of anti-aggregatory effects of aortic valve tissue in patients with aortic stenosis.
Chirkov YY; Mishra K; Chandy S; Holmes AS; Kanna R; Horowitz JD
J Heart Valve Dis; 2006 Jan; 15(1):28-33. PubMed ID: 16480009
[TBL] [Abstract][Full Text] [Related]
8. Platelet resistance to the antiaggregating effect of N-acetyl-L-cysteine in obese, insulin-resistant subjects.
Anfossi G; Russo I; Massucco P; Mattiello L; Trovati M
Thromb Res; 2003 Apr; 110(1):39-46. PubMed ID: 12877907
[TBL] [Abstract][Full Text] [Related]
9. Combined administration of nitric oxide gas and iloprost during cardiopulmonary bypass reduces platelet dysfunction: a pilot clinical study.
Chung A; Wildhirt SM; Wang S; Koshal A; Radomski MW
J Thorac Cardiovasc Surg; 2005 Apr; 129(4):782-90. PubMed ID: 15821644
[TBL] [Abstract][Full Text] [Related]
10. Nitrovasodilators and cGMP inhibit human platelet activation.
Doni MG; Alexandre A; Padoin E; Bertoncello S; Deana R
Cardioscience; 1991 Sep; 2(3):161-5. PubMed ID: 1660321
[TBL] [Abstract][Full Text] [Related]
11. Adenosine diphosphate-induced aggregation is enhanced in platelets obtained from patients with thrombotic primary antiphospholipid syndrome (t-PAPS): Role of P2Y
Leonardi GR; Lescano CH; Costa JL; Mazetto B; Orsi FA; Monica FZ
J Thromb Haemost; 2022 Jul; 20(7):1699-1711. PubMed ID: 35395698
[TBL] [Abstract][Full Text] [Related]
12. Evidence for a cyclic GMP-independent mechanism in the anti-platelet action of S-nitrosoglutathione.
Gordge MP; Hothersall JS; Noronha-Dutra AA
Br J Pharmacol; 1998 May; 124(1):141-8. PubMed ID: 9630353
[TBL] [Abstract][Full Text] [Related]
13. Regulation of protease-activated receptor (PAR) 1 and PAR4 signaling in human platelets by compartmentalized cyclic nucleotide actions.
Bilodeau ML; Hamm HE
J Pharmacol Exp Ther; 2007 Aug; 322(2):778-88. PubMed ID: 17525299
[TBL] [Abstract][Full Text] [Related]
14. Adenosine increases human platelet levels of cGMP through nitric oxide: possible role in its antiaggregating effect.
Anfossi G; Russo I; Massucco P; Mattiello L; Cavalot F; Balbo A; Trovati M
Thromb Res; 2002 Jan; 105(1):71-8. PubMed ID: 11864710
[TBL] [Abstract][Full Text] [Related]
15. Platelet receptor desensitization induced by elevated prostacyclin levels causes platelet-endothelial cell adhesion.
Darius H; Binz C; Veit K; Fisch A; Meyer J
J Am Coll Cardiol; 1995 Sep; 26(3):800-6. PubMed ID: 7543911
[TBL] [Abstract][Full Text] [Related]
16. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.
Maurice DH; Haslam RJ
Mol Pharmacol; 1990 May; 37(5):671-81. PubMed ID: 2160060
[TBL] [Abstract][Full Text] [Related]
17. Cyclic GMP but not cyclic AMP prevents renal platelet accumulation after ischemia-reperfusion in anesthetized rats.
Chintala MS; Bernardino V; Chiu PJ
J Pharmacol Exp Ther; 1994 Dec; 271(3):1203-8. PubMed ID: 7996427
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of human platelet aggregation by endothelium-derived relaxing factor, sodium nitroprusside or iloprost is potentiated by captopril and reduced thiols.
Mollace V; Salvemini D; Sessa WC; Vane JR
J Pharmacol Exp Ther; 1991 Sep; 258(3):820-3. PubMed ID: 1716310
[TBL] [Abstract][Full Text] [Related]
19. The activity of constitutive nitric oxide synthase is increased by the pathway cAMP/cAMP-activated protein kinase in human platelets. New insights into the antiaggregating effects of cAMP-elevating agents.
Russo I; Doronzo G; Mattiello L; De Salve A; Trovati M; Anfossi G
Thromb Res; 2004; 114(4):265-73. PubMed ID: 15381390
[TBL] [Abstract][Full Text] [Related]
20. The effect of Sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5.
Dunkern TR; Hatzelmann A
Cell Signal; 2005 Mar; 17(3):331-9. PubMed ID: 15567064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
